TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19726907

Group type: EXPERIMENTAL
Intervention: Nutritional program including a feeding protocol and feeding flow
Number of subjects: 38

Group type: COMPARATOR
Intervention: Usual feeding care (control group)
Number of subjects: 38
Study: 17786418

Group type: EXPERIMENTAL
Intervention: Dihydrocodeine 60 mg
Number of subjects: 9
Study: 15261923

Group type: EXPERIMENTAL
Intervention: Balloon angioplasty
Number of subjects: 1301

Group type: EXPERIMENTAL
Intervention: Balloon angioplasty + abciximab
Number of subjects: 1301

Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 1301

Group type: EXPERIMENTAL
Intervention: Stenting + abciximab
Number of subjects: 1301

Group type: COMPARATOR
Intervention: Thrombolysis In Myocardial Infarction flow grade 3 restoration
Number of subjects: 1301
Study: 12486341

Group type: EXPERIMENTAL
Intervention: Passive prone extensions of the back
Number of subjects: 249

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 249
Study: 9473085

Group type: EXPERIMENTAL
Intervention: Nucleus 22 and Med-El Combi 40 cochlear implants
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Stimulation with sound field broad-band 80-dB noise
Number of subjects: 17
Study: 7637722

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 97
Study: 2474103

Group type: EXPERIMENTAL
Intervention: Dietary sodium restriction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme (ACE) inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of dietary sodium restriction and ACE inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Addition of a thiazide diuretic
Number of subjects: 0
Study: 320712

Group type: EXPERIMENTAL
Intervention: Treatment with factor VIII or factor IX concentrate and a reducing dose of prednisolone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 30
Study: 30058460

Group type: EXPERIMENTAL
Intervention: Montmorency cherry concentrate (MC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 20
Study: 28753698

Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy plus large-balloon dilation (ES-LBD)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional endoscopic sphincterotomy (without balloon dilation)
Number of subjects: 150
Study: 26333778

Group type: EXPERIMENTAL
Intervention: Standard antimicrobial therapy plus daily granulocyte transfusions from donors stimulated with G-CSF and dexamethasone
Number of subjects: 114

Group type: COMPARATOR
Intervention: Standard antimicrobial therapy
Number of subjects: 114
Study: 23294689

Group type: EXPERIMENTAL
Intervention: Segmental counterstrain OMT
Number of subjects: 240

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 240
Study: 21608218

Group type: EXPERIMENTAL
Intervention: Electro‐needling at acupoints of the yangming meridian
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional therapies (Control group)
Number of subjects: 58
Study: 19472910

Group type: EXPERIMENTAL
Intervention: Thulium laser (Th group)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Both groups (Ho and Th)
Number of subjects: 98
Study: 17454132

Group type: EXPERIMENTAL
Intervention: Legume enriched diet (4 days/week servings)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control diet (CD)
Number of subjects: 30
Study: 15083284

Group type: EXPERIMENTAL
Intervention: Natalizumab (3 mg/kg or 6 mg/kg)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study: 11313245

Group type: EXPERIMENTAL
Intervention: Allogeneic peripheral blood hematopoietic stem cell transplantation (PBHSCT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Bone marrow hematopoietic stem cell transplantation (BMHSCT)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: PBHSCT with minor ABO mismatch
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: PBHSCT without minor ABO mismatch
Number of subjects: 49

Group type: COMPARATOR
Intervention: BMHSCT with minor ABO mismatch
Number of subjects: 49

Group type: COMPARATOR
Intervention: BMHSCT without minor ABO mismatch
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: PBHSCT
Number of subjects: 49

Group type: COMPARATOR
Intervention: BMHSCT
Number of subjects: 49
Study: 9453087

Group type: EXPERIMENTAL
Intervention: SACH prosthetic mechanism
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dynamic prosthetic mechanism
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Single-axis prosthetic mechanism
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Greissinger prosthetic mechanism
Number of subjects: 8
Study: 7948819

Group type: EXPERIMENTAL
Intervention: Branched-chain amino acid solution (Aminoleban), intravenous infusion for 3 hours
Number of subjects: 6
Study: 3373659

Group type: EXPERIMENTAL
Intervention: Diltiazem hydrochloride
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 29274894

Group type: EXPERIMENTAL
Intervention: Internet-based walking program with tailored step-count goals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telephone counseling to promote walking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of telephone counseling with the internet-based walking program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study: 27528177

Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg 3 times daily for 2 weeks
Number of subjects: 636

Group type: COMPARATOR
Intervention: Placebo 3 times daily for 2 weeks
Number of subjects: 636
Study: 24633376

Group type: EXPERIMENTAL
Intervention: Hearing aids
Number of subjects: 102

Group type: COMPARATOR
Intervention: Headphones
Number of subjects: 102
Study: 23423920

Group type: EXPERIMENTAL
Intervention: Coregistered MRI-PET
Number of subjects: 263

Group type: COMPARATOR
Intervention: PET-CT plus brain MRI
Number of subjects: 263
Study: 19108789

Group type: EXPERIMENTAL
Intervention: Test formulation (T4 Montpellier 100)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation (Synthroid)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Test formulation (T4 Montpellier 100) with baseline adjustment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation (Synthroid) with baseline adjustment
Number of subjects: 24
Study: 15996609

Group type: COMPARATOR
Intervention: Heat wrap therapy alone (n=25)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Directional preference‐based exercise alone (n=25)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination of heat wrap therapy and exercise (heat+exercise, n=24)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (booklet, n=26)
Number of subjects: 100
Study: 14681952

Group type: EXPERIMENTAL
Intervention: Screen-detected diagnosis of colorectal cancer through flexible sigmoidoscopy screening
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Screen-detected diagnosis of colorectal cancer
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Raising awareness of the adenoma-carcinoma sequence
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Interventions aimed at reducing distress of screen-detected cancer
Number of subjects: 24
Study: 10668692

Group type: EXPERIMENTAL
Intervention: 11C-flumazenil (FMZ) PET
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: SPM analysis
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 10
Study: 8694321

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg daily
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg daily
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 1435624

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study: 6705280

Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 30226022

Group type: EXPERIMENTAL
Intervention: Violent FPS game that rewarded headshots
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonviolent shooting game that punished hits to bull's-eye targets with faces
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonviolent non-shooting game
Number of subjects: 0
Study: 29160486

Group type: EXPERIMENTAL
Intervention: Dramatic Therapeutic Play (DTP)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study: 26051022

Group type: EXPERIMENTAL
Intervention: Telephone-based cognitive-behavioral therapy (CBT) intervention
Number of subjects: 273

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 273
Study: 23515142

Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg per kg bodyweight intravenously every 4 weeks plus placebo subcutaneously every 2 weeks
Number of subjects: 326

Group type: COMPARATOR
Intervention: Adalimumab 40 mg subcutaneously every 2 weeks plus placebo intravenously every 4 weeks
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 326

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 326
Study: 21333268

Group type: EXPERIMENTAL
Intervention: Trichiasis surgery
Number of subjects: 438
Study: 19831164

Group type: EXPERIMENTAL
Intervention: 8.0% arginine toothpaste
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control toothpaste
Number of subjects: 120

Group type: COMPARATOR
Intervention: Benchmark desensitizing toothpaste
Number of subjects: 120
Study: 16618953

Group type: EXPERIMENTAL
Intervention: Telephone support intervention (average of 4 calls over 18 months)
Number of subjects: 1413

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1413
Study: 14602286

Group type: EXPERIMENTAL
Intervention: SJM‐AHPJ 21 mm
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: SJM‐Regent 21 mm
Number of subjects: 47

Group type: COMPARATOR
Intervention: CM 21 mm
Number of subjects: 47

Group type: COMPARATOR
Intervention: CM 23 mm
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: SJM‐AHPJ 23 mm
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: SJM‐Regent 23 mm
Number of subjects: 47
Study: 10350034

Group type: EXPERIMENTAL
Intervention: Buspirone (20-60 mg/day, mean daily dose 48.5 mg)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 8606118

Group type: EXPERIMENTAL
Intervention: Bivalent vaccine composed of Vibrio cholerae CVD 103‐HgR and Salmonella typhi Ty21a
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study: 1954640

Group type: EXPERIMENTAL
Intervention: 0.025% capsaicin cream applied four times daily for four weeks
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo (vehicle cream)
Number of subjects: 101
Study: 7318332

Group type: EXPERIMENTAL
Intervention: Dihydralazine (16.2‐32.4 mg/2 h) plus saline
Number of subjects: 4

Group type: COMPARATOR
Intervention: Dihydralazine (16.2‐32.4 mg/2 h) plus diclofenac (75 mg/20 ml saline)
Number of subjects: 4
Study: 6499689

Group type: EXPERIMENTAL
Intervention: TTS-scopolamine
Number of subjects: 46

Group type: COMPARATOR
Intervention: Meclozine tablets
Number of subjects: 46
Study: 30269698

Group type: EXPERIMENTAL
Intervention: MCP‐palliative care version
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: MCP‐compassionate palliative care (MCP‐CPC)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard counseling
Number of subjects: 51
Study: 26823208

Group type: EXPERIMENTAL
Intervention: Uterine artery (UtA) Doppler screening
Number of subjects: 11667

Group type: COMPARATOR
Intervention: Non-Doppler group
Number of subjects: 11667
Study: 24377410

Group type: EXPERIMENTAL
Intervention: modified cognitive behavioral therapy (m-CBT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: usual care (UC) therapy
Number of subjects: 43
Study: 22656189

Group type: EXPERIMENTAL
Intervention: Han-uvulopalatopharyngoplasty (H‐UPPP)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (normal PSG)
Number of subjects: 49
Study: 19533356

Group type: EXPERIMENTAL
Intervention: Esomeprazole (40 mg by mouth every morning)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Aerosolized, swallowed fluticasone (440 mcg by mouth twice a day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Esomeprazole
Number of subjects: 25

Group type: COMPARATOR
Intervention: Fluticasone
Number of subjects: 25
Study: 18476433

Group type: EXPERIMENTAL
Intervention: Tongdatang serial recipe (TDT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 15839957

Group type: EXPERIMENTAL
Intervention: gemcitabine-carboplatin
Number of subjects: 356

Group type: COMPARATOR
Intervention: carboplatin
Number of subjects: 356
Study: 12599218

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy for Stage II breast carcinoma
Number of subjects: 0
Study: 10228115

Group type: EXPERIMENTAL
Intervention: Target Dyspnea Rating (TDR)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Target Heart Rate (THR)
Number of subjects: 44
Study: 8712160

Group type: EXPERIMENTAL
Intervention: HGSHS: A and SHSS:C
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: CIS and SHSS:C
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: HGSHS: A and SHCS:A
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: CIS and SHCS:A
Number of subjects: 280

Group type: COMPARATOR
Intervention: SHSS:C alone
Number of subjects: 280
Study: 2064139

Group type: EXPERIMENTAL
Intervention: Inhaled methacholine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled metaproterenol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physiologic variables (peak inspiratory flow, tidal volume/FVC, frequency of respiration, peak inspiratory mouth pressures)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Borg rating of breathlessness
Number of subjects: 0

Group type: COMPARATOR
Intervention: Test-retest reliability
Number of subjects: 0

Group type: COMPARATOR
Intervention: Work intensity (watts)
Number of subjects: 0
Study: 7109137

Group type: EXPERIMENTAL
Intervention: Individualized method for calculating gentamicin dosage
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Dettli method
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Chan method
Number of subjects: 96

Group type: COMPARATOR
Intervention: Sarubbi‐Hull method
Number of subjects: 96

Group type: COMPARATOR
Intervention: Rule of eights method
Number of subjects: 96
Study: 31238081

Group type: EXPERIMENTAL
Intervention: Soy beverage (200 ml consumed once a day for 15 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bovine milk (200 ml consumed once a day for 15 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both beverages
Number of subjects: 0
Study: 30307902

Group type: COMPARATOR
Intervention: IVIG
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: IVIG + Infliximab
Number of subjects: 154
Study: 26875114

Group type: EXPERIMENTAL
Intervention: Buspirone (20mg p.o.)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ergotamine (3mg p.o.)
Number of subjects: 36
Study: 25440374

Group type: EXPERIMENTAL
Intervention: Shenzhu Tiaopi granule (SZTP) plus lifestyle intervention
Number of subjects: 514

Group type: COMPARATOR
Intervention: Lifestyle intervention (control group)
Number of subjects: 514
Study: 21719715

Group type: EXPERIMENTAL
Intervention: Combined clinic (CC)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Standard care (MC)
Number of subjects: 139
Study: 20649426

Group type: EXPERIMENTAL
Intervention: Acyclovir (400 mg, twice daily)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 18041171

Group type: EXPERIMENTAL
Intervention: Grazax (oral vaccine)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 16335327

Group type: EXPERIMENTAL
Intervention: MWT1 sleep latency under partial sleep deprivation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MWT1 sleep latency under partial sleep deprivation and alcohol condition
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MWT1 sleep latency in the partial sleep deprivation plus alcohol condition
Number of subjects: 20
Study: 12538215

Group type: EXPERIMENTAL
Intervention: Bupivacaine microcapsules (0.3125% to 5.0%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bupivacaine microcapsules (2.5%) with dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.25% aqueous bupivacaine
Number of subjects: 0
Study: 9917081

Group type: EXPERIMENTAL
Intervention: Tramadol titrated at 10 days to achieve 200 mg/day
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Tramadol titrated at 4 days to achieve 200 mg/day
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Tramadol titrated at 1 day to achieve 200 mg/day
Number of subjects: 465

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 465
Study: 7494615

Group type: EXPERIMENTAL
Intervention: F60S
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: SPAN
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: PAN
Number of subjects: 9
Study: 1962781

Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy and thoracic irradiation
Number of subjects: 0
Study: 7282733

Group type: EXPERIMENTAL
Intervention: Aerosol metaproterenol (3 puffs)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral aminophylline (0.4 to 0.6 g)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination of both (aminophylline and metaproterenol)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31121136

Group type: EXPERIMENTAL
Intervention: Pregnancy
Number of subjects: 14335

Group type: EXPERIMENTAL
Intervention: Vaginal delivery
Number of subjects: 14335

Group type: COMPARATOR
Intervention: Cesarean delivery
Number of subjects: 14335
Study: 23242955

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 310
Study: 21706943

Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP) based ART
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) based ART
Number of subjects: 134

Group type: COMPARATOR
Intervention: NVP and EFV (combined)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: HCV co-infection
Number of subjects: 134
Study: 19422982

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 607

Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 607
Study: 16397159

Group type: EXPERIMENTAL
Intervention: Multisite physical activity intervention program developed from formative research
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Formative research conducted through interviews with principals and physical education department heads
Number of subjects: 64
Study: 15576957

Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kyphoplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 11089714

Group type: EXPERIMENTAL
Intervention: EBM course, taught 2 hours per week for 7 consecutive weeks by senior faculty and chief residents
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group after it crossed over to receive the intervention
Number of subjects: 55
Study: 9165972

Group type: EXPERIMENTAL
Intervention: Delivery of oxygen at 21.min‐1 via nasal cannulae
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oxygen directed from under the surgical drapes
Number of subjects: 30
Study: 8239103

Group type: EXPERIMENTAL
Intervention: 240 mg methylprednisolone acetate suspension
Number of subjects: 70

Group type: COMPARATOR
Intervention: IM saline placebo
Number of subjects: 70
Study: 3701584

Group type: EXPERIMENTAL
Intervention: Superimposed slide images
Number of subjects: 39

Group type: COMPARATOR
Intervention: Figure-ground composite images
Number of subjects: 39
Study: 30094809

Group type: EXPERIMENTAL
Intervention: Modified Care Transitions Intervention (CTI) delivered by community paramedics
Number of subjects: 422
Study: 25972203

Group type: EXPERIMENTAL
Intervention: CrossFit Teens™ resistance training programme (60 min, twice per week for 8 weeks)
Number of subjects: 96
Study: 25939638

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (0.1 mg/kg body weight) and nitrous oxide‐oxygen sedation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oral midazolam (0.2 mg/kg body weight) and nitrous oxide‐oxygen sedation
Number of subjects: 30
Study: 23473703

Group type: EXPERIMENTAL
Intervention: Driven gait orthosis (DGO)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Treadmill-based locomotor training with manual assistance (TM)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation (TS)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Overground locomotor training with electrical stimulation (OG)
Number of subjects: 62
Study: 21778716

Group type: EXPERIMENTAL
Intervention: M-EDTA
Number of subjects: 50

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 50
Study: 19433697

Group type: EXPERIMENTAL
Intervention: Individualized acupuncture
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Standardized acupuncture
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Simulated acupuncture
Number of subjects: 638

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Individualized, standardized, or simulated acupuncture
Number of subjects: 638
Study: 16421476

Group type: EXPERIMENTAL
Intervention: Losartan 50-100 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Carvedilol 12.5-25 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 15351409

Group type: EXPERIMENTAL
Intervention: Mobile bearing (group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fixed bearing (group A)
Number of subjects: 40
Study: 11545670

Group type: EXPERIMENTAL
Intervention: Integrated care clinic (n = 59)
Number of subjects: 120

Group type: COMPARATOR
Intervention: General medicine clinic (n = 61)
Number of subjects: 120
Study: 9259053

Group type: EXPERIMENTAL
Intervention: Aminophylline (nonspecific competitive adenosine receptor antagonist)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 7864610

Group type: EXPERIMENTAL
Intervention: 10% sucrose yogurt
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 5% and 10% sucrose yogurt
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intake days (yogurt consumption)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sensory evaluation days (no yogurt consumption)
Number of subjects: 10